SCHEMBL2008513

SCHEMBL2008513

Fc1cccc(Cc2nsc(N3CCNCC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.48
HTR2B P41595 3/20 0.48
HTR6 P50406 9/20 0.44
HTR1A P08908 6/20 0.42
HTR2A P28223 5/20 0.42
HTR7 P34969 4/20 0.42
DRD2 P14416 3/20 0.42
PRMT5 O14744 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
CSNK1A1 P48729 1/20 0.39
SLC6A2 P23975 2/20 0.39
SLC6A4 P31645 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CETP P11597 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008099 0.95 HTR2B (0.45) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL2009116 0.85 HTR2C (0.48) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL1021015 0.84 HTR2B (0.44) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL2007325 0.84 TAAR1 (0.51) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL2004219 0.84 HTR6 (0.42) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL1022439 0.82 ADRB1 (0.51) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL2005298 0.81 HTR6 (0.48) HTR6DRD2SLC6A4MEN1KMT2A
SCHEMBL2005415 0.81 HTR2C (0.45) HTR2CHTR2BHTR6HTR1AHTR2A
SCHEMBL2008851 0.81 SOS1 (0.50) HTR6CETP
SCHEMBL2008248 0.80 HTR2B (0.43) HTR2CHTR2BHTR6HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed
EP-2094677-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV Remynd (BE) 2009-09-02 EP disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed
WO-2008061781-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP HTR2C 1846/4885HTR2B 2061/4885HTR6 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.